Teva Pharmaceutical Industries (NYSE: TEVA) reports proposed insider sales of ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries submitted notices under Form 144 reporting proposed sales of ordinary shares by affiliated holders. The filings list multiple planned dispositions dated 03/03/2026 and 03/04/2026, and record a prior sale of 345,810 shares on 02/26/2026.

Key Figures

Proposed lot 1: 110,668 shares Proposed lot 2: 19,332 shares Proposed lot 3: 23,251 shares +3 more

6 metrics

Proposed lot 1 110,668 shares dated 03/03/2026; rollover

Proposed lot 2 19,332 shares dated 03/03/2026; compensation

Proposed lot 3 23,251 shares dated 03/04/2026; rollover

Recent sale reported 345,810 shares sold on 02/26/2026 in past 3 months

Aggregate amount for prior sale $11,634,702.06 associated with 345,810 shares on 02/26/2026

Form header date 05/14/2026 Form 144 filing header date

Key Terms

Form 144, ordinary shares, rollover, compensation

4 terms

Form 144 regulatory

"submitted notices under Form 144 reporting proposed sales"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

ordinary shares financial

"lists of ORDINARY SHARES for sale and prior sale entries"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

rollover financial

"SHARES FROM ROLLOVER listed with dates 03/03/2026 and 03/04/2026"

compensation financial

"COMPENSATION ORDINARY SHARES shown for multiple lots"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	153251	5457368.64	1164426972	05/14/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			110668	05/14/2026	COMPENSATION
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			19332	05/14/2026	COMPENSATION
ORDINARY SHARES	03/04/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			23251	05/14/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kalif Eliyahu Sharon TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	02/26/2026	345810	11634702.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does TEVA's Form 144 filing disclose?

The filing discloses proposed sales of Teva ordinary shares by affiliates. It lists rollovers and compensation-related share lots dated 03/03/2026 and 03/04/2026, and a prior sale of 345,810 shares on 02/26/2026 valued at $11,634,702.06.

How many shares are listed for proposed sale in the TEVA excerpt?

The excerpt lists specific lots including 110,668, 19,332, and 23,251 ordinary shares tied to rollover and compensation transactions dated March 2026. These appear as proposed dispositions in the Form 144 notices filed on 05/14/2026.

Was there recent share activity reported for TEVA insiders?

Yes. The filing shows a sale during the past three months: 345,810 shares sold on 02/26/2026 with an aggregate amount listed as $11,634,702.06. That transaction is reported in the Form 144 excerpt.

What dates are associated with the TEVA Form 144 entries?

Key dates in the excerpt include proposed sale dates 03/03/2026 and 03/04/2026 for specific lots, the prior sale date 02/26/2026, and the filing/reporting date shown as 05/14/2026 on the Form 144 header.